^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
danvilostomig (SI-B003)
i
Other names: SI-B003, SI B003, SIB003
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Biokin Pharma
Drug class:
PD1 inhibitor, CTLA4 inhibitor
Related drugs:
2ms
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=130, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
izalontamab (SI-B001) • danvilostomig (SI-B003)
2ms
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors (clinicaltrials.gov)
P2, N=376, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
2ms
BL-B01D1-SI-B003-201-03: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (clinicaltrials.gov)
P2, N=186, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Oct 2025 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
2ms
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors (clinicaltrials.gov)
P2, N=52, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
2ms
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=160, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion
|
izalontamab (SI-B001) • danvilostomig (SI-B003)
2ms
BL-B01D1-SI-B003-201-02: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=100, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
2ms
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=159 --> 60
Enrollment closed • Enrollment change
|
danvilostomig (SI-B003)
2ms
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (clinicaltrials.gov)
P2, N=121, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
EGFR wild-type
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
2ms
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies (clinicaltrials.gov)
P2, N=130, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
HRD • BRCA mutation
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
2ms
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov)
P2, N=58, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)
3ms
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=159, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
Trial completion date • Trial primary completion date
|
danvilostomig (SI-B003)
4ms
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=130, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | N=40 --> 130 | Trial primary completion date: Jun 2025 --> Dec 2025
Enrollment change • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
izalontamab (SI-B001) • danvilostomig (SI-B003)
Share via
